Cheng Schwank-Xu

Dr. Cheng Schwank-Xu


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 May 2021 in Antioxidants
Verified
Journal Article
Open access
PDF file
CSCheng Schwank-Xu
Cheng Schwank-Xu
EFElisabete Forsberg
Elisabete Forsberg
MBMagnus Bentinger
Magnus Bentinger
AZAllan Zhao
Allan Zhao
IAIshrath Ansurudeen
Ishrath Ansurudeen
MTMichael Tekle
Michael Tekle
Mitochondrial dysfunction in type 2 diabetes leads to oxidative stress, which drives disease progression and diabetes complications. L-carnosine, an endogenous dipeptide, improves metabolic control, wound healing and kidney function in animal models of type 2 diabetes. Coenzyme Q (CoQ), a component of the mitochondrial electron transport chain, possesses similar protective effects on diabetes complications. We aimed to study the effect of carnosine on CoQ, and assess any synergistic effects of carnosine and CoQ on improved mitochondrial function in a mouse model of type 2 diabetes. Carnosine enhanced CoQ gene expression and increased hepatic CoQ biosynthesis in db/db mice, a type 2 diabetes model. Co-administration of Carnosine and CoQ improved mitochondrial function, lowered ROS formation and reduced signs of oxidative stress. Our work suggests that carnosine exerts beneficial effects on hepatic CoQ synthesis and when combined with CoQ, improves mitochondrial function and cellular redox balance in the liver of diabetic mice. (4) Conclusions: L-carnosine has beneficial effects on oxidative stress both alone and in combination with CoQ on hepatic mitochondrial function in an obese type 2 diabetes mouse model.

1 January 2017 in Journal of Diabetes and its Complications
Verified
Journal Article
Closed access
CSCheng Schwank-Xu
Cheng Schwank-Xu
MBMagnus Bentinger
Magnus Bentinger
OSOctavian Savu
Octavian Savu
AMAli Moshfegh
Ali Moshfegh
VSVivekananda Sunkari
Vivekananda Sunkari
MTMichael Tekle
Michael Tekle

1 November 2015 in Journal of Diabetes and its Complications
Verified
Journal Article
Closed access
EFElisabete Forsberg
Elisabete Forsberg
CSCheng Schwank-Xu
Cheng Schwank-Xu
JGJacob Grünler
Jacob Grünler
JFJohan Frostegård
Johan Frostegård
MTMichael Tekle
Michael Tekle
LKLars Kärvestedt
Lars Kärvestedt

11 November 2020 in FEBS Open Bio
Verified
Journal Article
Open access
PDF file
WXWang Xiaoli
Wang Xiaoli
HLHua Li
Hua Li
DLDong Li
Dong Li
YBYudi Bai
Yudi Bai
YZYao Zhang
Yao Zhang
TZTao Zhang
Tao Zhang
Sorafenib, the first‐line agent for treatment of advanced hepatocellular carcinoma (HCC), improves median overall survival by approximately 3 months. In the present study, we investigated whether sorafenib combined with cucurbitacin B (CuB), a natural tetracyclic triterpenoid isolated from Cucurbitaceae, exerts enhanced antitumor effects against HCC. Cell viability and colony formation ability were detected by cell‐counting kit‐8 and colony formation assays. Cell cycle and apoptosis were analyzed by flow cytometry. Protein expression was detected by western blotting. HepG2 xenografts in nude mice were used to evaluate in vivo antitumor effects. We report that sorafenib and CuB exhibited synergistic effects on cellular proliferation inhibition and cell apoptosis induction, but not on cell cycle arrest. Furthermore, combination treatment enhanced levels of cleaved caspase 3 and cleaved caspase 9, but suppressed phosphorylation of STAT3. Epidermal growth factor, a potent stimulator of signal transducer and activator of transcription‐3 (STAT3), promoted cell viability and colony formation ability, whereas combination treatment exerted inhibitory effects on epidermal growth factor‐induced STAT3 phosphorylation. Finally, HepG2 xenograft mice cotreated with sorafenib and CuB exhibited reduced tumor progression without notable weight loss. In conclusion, sorafenib and CuB exert synergistic antitumor effects through a pathway that may involve STAT3 phosphorylation, and this may represent a promising therapeutic approach for treatment of HCC.

2 July 2021 in Antioxidants
Verified
Journal Article
Open access
PDF file
GDGustav Dallner
Gustav Dallner
MBMagnus Bentinger
Magnus Bentinger
SHShafaat Hussain
Shafaat Hussain
ISIndranil Sinha
Indranil Sinha
JYJiangning Yang
Jiangning Yang
MTMichael Tekle
Michael Tekle
Hyperglycemia, hyperlipidemia, and adiposity are the main factors that cause inflammation in type 2 diabetes due to excessive ROS production, leading to late complications. To counteract the effects of increased free radical production, we searched for a compound with effective antioxidant properties that can induce coenzyme Q biosynthesis without affecting normal cellular functions. Tocotrienols are members of the vitamin E family, well-known as efficient antioxidants that are more effective than tocopherols. Deh-T3β is a modified form of the naturally occurring tocotrienol-β. The synthesis of this compound involves the sequential modification of geranylgeraniol. In this study, we investigated the effects of this compound in different experimental models of diabetes complications. Deh-T3β was found to possess multifaceted capacities. In addition to enhanced wound healing, deh-T3β improved kidney and liver functions, reduced liver steatosis, and improved heart recovery after ischemia and insulin sensitivity in adipose tissue in a mice model of type 2 diabetes. Deh-T3β exerts these positive effects in several organs of the diabetic mice without reducing the non-fasting blood glucose levels, suggesting that both its antioxidant properties and improvement in mitochondrial function are involved, which are central to reducing diabetes complications.